HUTCHMED (China) Ltd (HCM) (Q4 2024) Earnings Call Highlights: Achieving Profitability and ... [Yahoo! Finance]
HUTCHMED (China) Limited - American Depositary Shares (HCM)
NASDAQ:AMEX Investor Relations:
chi-med.com/investors/information-for-shareholders
Company Research
Source: Yahoo! Finance
Net Income: $37 million. Oncology Business Revenue: Over $360 million. Cash Resources: Over $830 million, a reduction of around $50 million from 2023. 2025 Oncology Revenue Guidance: $350 million to $450 million. In-Market Sales: Oncology portfolio sales of $0.5 billion, more than double the sales of 2023. ELUNATE Sales: Achieved $115 million in 2025. Warning! GuruFocus has detected 4 Warning Sign with HCM. Release Date: March 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript HUTCHMED (China) Ltd ( NASDAQ:HCM ) reported a net profit for 2024, achieving profitability ahead of schedule. FRUZAQLA achieved global commercial success with total sales of $290.6 million. Savolitinib rec
Read more
Impact Snapshot
Event Time:
HCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCM alerts
High impacting HUTCHMED (China) Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
HCM
News
- HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]Yahoo! Finance
- HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular LymphomaGlobeNewswire
- Intended Retirement of Independent Non-executive Directors and changes of composition of board committeesGlobeNewswire
- HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 [Yahoo! Finance]Yahoo! Finance
HCM
Sec Filings
- 3/31/25 - Form 6-K
- 3/21/25 - Form 6-K
- 3/20/25 - Form 6-K
- HCM's page on the SEC website